Estrogen receptor (ER)-negative breast cancers, including triple-negative and HER2-positive subtypes, have higher levels of immune infiltration when compared to ER-positive (luminal) breast cancers [22,23]. This evidence concerns the gene ESR1 and breast carcinoma.